Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Treatment of Radiation and Cisplatin Induced Toxicities with Tempol
NCT03480971 · View on ClinicalTrials.gov ↗
Study Summary
A 10 week trial to assess the ability of Tempol to prevent and/or reduce toxicities associated with cisplatin and radiation treatment in head and neck cancer patients. Over the course of the 10 week trial, mucositis, nephrotoxicity, and ototoxicity will be monitored and assessed.
Conditions Studied
Interventions
- DRUG Tempol
- DRUG Placebo Solution
Study Locations (9)
California
- UCSD — La Jolla
- Mercy Medical Center — Merced
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco
- Central Coast Medical Oncology — Santa Maria
- Mission Hope Health Center — Santa Maria
Washington
- Seattle Cancer Care Alliance — Seattle
- University of Washington Medical Center — Seattle
New York
- Montefiore Medical Center-Einstein Campus — The Bronx
North Carolina
- Wake Forest University Health Sciences — Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2019-05-13 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03480971
The ClinicalTrials.gov registry entry for NCT03480971 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Matrix Biomed, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Mucositis appearing as the primary indexed condition, and to 2 interventions — of which Tempol is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03480971 reports 9 study locations spanning 4 distinct geographic areas — top geographies include California, Washington, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03480971 about?
NCT03480971 is a clinical study titled "Treatment of Radiation and Cisplatin Induced Toxicities with Tempol". A 10 week trial to assess the ability of Tempol to prevent and/or reduce toxicities associated with cisplatin and radiation treatment in head and neck cancer patients. Over the course of the 10 week trial, mucositis, nephrotoxicity, and ototoxicity will be monitored and assessed.
What is the current status of trial NCT03480971?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2019-05-13. Estimated completion is 2025-12.
What conditions does trial NCT03480971 study?
This clinical trial studies the following conditions: Mucositis, Ototoxicity, Nephrotoxicity. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03480971?
The interventions under investigation include: Tempol (DRUG), Placebo Solution (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03480971?
This trial is sponsored by Matrix Biomed, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03480971 being conducted?
This trial has 9 study locations across California, New York, North Carolina, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.